Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 15, 2022
Most recently, the Center for Global Development hosted two conferences—the first is the Bali Care Economy Dialogue, a collaborative effort with The Asia Foundation and other partners alongside the G20, and the second our annual Birdsall House Conference on Gender Equality, this year focused on chil...
Blog Post
December 15, 2022
Dr. Yi-Chun Lo of Taiwan’s Centers for Disease Control and National Taiwan University Hospital joins Javier Guzman to discuss Taiwan’s COVID-19 experience and broader pandemic preparedness and response efforts. Together, they discuss the lessons Taiwan learned from previous outbreaks like SARS, succ...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
CGD NOTES
December 13, 2022
The unprecedented turnout at rallies across Pakistan protesting corruption and poor job prospects underscores the frustration among the rapidly growing middle class with governance failures. Pakistan’s economic growth exceeded India’s for over four decades after its independence in 1947, but since t...
BRIEFS
December 08, 2022
Drug-resistant infections kill an estimated 23,210 Japanese citizens every year. The government of Japan is considering a program that would provide minimum guaranteed revenue to the successful developers of new antibiotics. We present the results of a modelling exercise to estimate the likely retur...
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...